secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2025-07-25T23:59:59+00:00
Accession:  0001193125-25-164853
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma raises up to $100M in private placement; initial $50M at $13.32/share
--------------------------------------------------------------------------------

- Initial closing of ~$50M from 3,753,752 shares at $13.32/share on July 25, 2025.
- Milestone closing option for another ~$50M upon LYL314 PiNACLE trial milestone within 12 months.
- Investor call option to purchase additional shares at $30.73/share before milestone closing.
- Proceeds to fund two pivotal-stage trials of LYL314 and extend cash runway into mid-2027.
- Resale registration rights granted; securities issued in exempt private placement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525164853/0001193125-25-164853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525164853/d24368d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-164853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer